Gitnux/Report 2026

Bioinformatics Industry Statistics

The global bioinformatics market is estimated at $21.36 billion in 2026, explore figures behind growth, companies, and trends.
210Statistics
70Sources
12Sections
1Visuals
40mRead
Bioinformatics Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The bioinformatics industry at a glance

The global bioinformatics market is estimated at $21.36 billion in 2026, with demand expanding as pharmaceutical R&D, genomics, cloud computing and AI increase the need to manage and interpret biological data.

$21.36B[55]
Global market size, 2026
15.2%[55]
Market growth, 2025–2026
59,600[56]
U.S. bioinformatics scientists, 2025
34.6%[57]
Genomics and transcriptomics share, 2025
Market size
The global bioinformatics market reached $18.54 billion in 2025 and is estimated at $21.36 billion in 2026. Estimates differ by market definition: Grand View Research valued the 2025 market at $20.1 billion.[55][58]
Forecast & CAGR
The Business Research Company forecasts growth from $21.36 billion in 2026 to $36.99 billion in 2030, representing a 14.7% CAGR. MarketsandMarkets forecasts the market rising from $18.63 billion in 2026 to $34.41 billion in 2031, at a 13.1% CAGR.[55][59]
Market share & regions
North America was the largest regional market in 2025, according to The Business Research Company. Mordor Intelligence reports that North America held the leading regional position, while Asia-Pacific is among the faster-growing markets; the available sources do not provide a consistent comparable percentage share.[55][57]
Segmentation
The market is commonly divided into knowledge-management tools, data-analysis platforms and services. Applications include genomics, transcriptomics, proteomics, metabolomics, molecular phylogenetics and chemoinformatics; genomics and transcriptomics together represented 34.6% of the market in 2025 in Mordor Intelligence’s segmentation.[55][57]
Pricing
Bioinformatics pricing spans cloud analysis, software platforms and fee-for-service work. Illumina states that secondary analysis of a 30–35x human whole genome typically costs $6–$10 per genome in the cloud, while a human whole-exome or transcriptome sample costs about $1.50–$2.50; UCLA lists external sequencing rates from $1,131.67 to $2,755.43 per MiSeq i100 run, effective July 1, 2026.[60][61]
Trends, drivers & challenges
Growth is being driven by rising sequencing-data volumes, pharmaceutical and biotechnology R&D, drug discovery, biomarker detection and clinical-trial applications. Key challenges include the cost of storage and computing, demand for specialized talent, data-governance requirements and the validation of AI-supported analyses for regulated uses.[59][62][63]
M&A
Industry activity includes both acquisitions and technology alliances. Illumina agreed in June 2025 to acquire SomaLogic from Standard BioTools, while QIAGEN and NVIDIA announced a 2026 collaboration combining QIAGEN Digital Insights’ curated bioinformatics knowledge with NVIDIA accelerated computing and BioNeMo for drug discovery.[64][16]
Regulation
Regulation is increasingly focused on AI, genomic-data governance and software used in regulated decision-making. In January 2025, the FDA issued draft guidance on AI supporting regulatory decisions for drugs and biological products; NIH also issued a March 2025 notice on protecting human genomic data when developing generative-AI tools, while FDA’s PDUFA VII program includes bioinformatics capacity, data standards and submission-validation work.[62][63]
Latest news
In 2026, QIAGEN announced that its Digital Insights bioinformatics business would integrate NVIDIA accelerated computing and the BioNeMo platform. The companies said the integration is intended to support target identification, biomarker research and hypothesis generation for pharmaceutical and biotechnology researchers.[16]

02 Ranking

Top 10 Companies in the Bioinformatics Industry

The leading companies in the bioinformatics industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Roche stands out for clinical sequencing-analysis because it develops navify and sequencing-analysis solutions for clinical genomics, while Oxford Nanopore Technologies leads in nanopore sequencing and analysis since it develops nanopore sequencing technology and associated analysis workflows.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in clinical genomics analytics

    Roche

    CH

    Ranked #1 · 9.3 · Clinical genomics analytics

    Why we picked it: Develops navify and sequencing-analysis solutions for clinical genomics, with revenue growth of 7% and R&D at 19.8% of revenue.

    See in ranking ↓Visit roche.com ↗

  2. Leader in sequencing and nanopore analysis

    Oxford Nanopore Technologies

    GB

    Ranked #2 · 9.0 · Sequencing and nanopore analysis

    Why we picked it: Develops nanopore sequencing technology and associated analysis workflows, backed by 22% revenue growth.

    See in ranking ↓Visit nanoporetech.com ↗

  3. Leader in genomic sequencing services

    BGI Group

    CN

    Ranked #3 · 8.9 · Genomic sequencing services

    Why we picked it: Provides genomic sequencing services plus bioinformatics and precision-medicine solutions.

    See in ranking ↓Visit bgi.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the bioinformatics industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Roche

Clinical genomics analytics · CH

9.3
2

Oxford Nanopore Technologies

Sequencing and nanopore analysis · GB

9.0
3

BGI Group

Genomic sequencing services · CN

8.9
4

Thermo Fisher Scientific

Genomics laboratory informatics · US

8.9
5

Agilent Technologies

Genomic data analysis · US

8.7
6

QIAGEN

Molecular analysis and bioinformatics software · NL

8.6
7

Dassault Systèmes

BIOVIA computational biology software · FR

8.6
8

Illumina

Sequencing, genomic analysis and bioinformatics · US

8.6
9

10x Genomics

Single-cell and spatial omics analysis · US

8.0
10

Bio-Rad Laboratories

Digital biology and genomic data analysis · US

7.7

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 11). Top 10 companies in the bioinformatics industry. In Bioinformatics Industry Statistics. Gitnux. https://gitnux.org/bioinformatics-industry-statistics/#top-companies

report visual · Comparison

Bioinformatics market revenue by region

North America leads with $14.7B.

North America$14.7B
Europe$9.1B
Asia Pacific$6.4B
Latin America$970.0M
Middle East and Africa$530.0M
source-verifiedfortunebusinessinsights.com

04 Statistics

Technology & Innovation

AI adoption is broad and operational by 2026, with 87% of surveyed life-sciences companies reporting integrated AI agents into processes, products, or services.

AI in the bioinformatics industry

  • 87% of surveyed life-sciences companies, including biotechnology firms, had integrated AI agents into processes, products or services in 2026, based on a survey of 124 technology executives.[1]
  • 36% of life-sciences companies had not started their generative-AI journey in 2023, according to a survey covering the sector’s technology adoption.[2]
  • 62% of surveyed biotechnology and biopharmaceutical organizations used AI regularly across R&D in 2025, while 38% used it in targeted use cases in the United States and Europe.[3]
  • 67% of large biopharma companies and 23% of small biopharma companies had adopted AI or machine learning in 2024, based on a survey of 300 U.S. and European professionals.[4]

Automation in the bioinformatics industry

  • 37% of respondents at small biopharma companies reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[3]
  • 63% of surveyed biopharma professionals reported using robotics and automation in 2023, according to a technology-adoption study of biopharmaceutical companies.[5]

Digital Transformation in the software and IT services sector (sector benchmark)

  • 75% of digital leaders globally planned to increase AI-related business expenditure in 2024.[6]
  • 72% of digital leaders globally expected to increase technology spending in 2024, compared with 50% of digital laggards, according to a survey of 855 technology and business decision-makers.[6]
  • 34% of surveyed organizations globally identified replacing or upgrading legacy technology as a top digital-transformation goal in 2024.[6]
  • 45% of North American technology and business decision-makers planned to adopt AI and machine learning to improve business within 12 to 24 months.[6]
  • 54.8% of surveyed organizations reported having a chief digital officer or another executive responsible for digital transformation.[7]

Technology Adoption in the software and IT services sector (sector benchmark)

  • 67.6% of IT services were delivered through cloud infrastructure among surveyed organizations in 2024.[7]
  • 51.8% of surveyed organizations reported that AI solutions were somewhat or extremely rare in 2024.[7]
  • More than 50% of surveyed global IT decision-makers were exploring AI use cases or piloting AI technologies in 2024.[6]
  • 57.7% of surveyed organizations reported having a chief information security officer or equivalent in 2024.[7]

Cloud Computing in the software and IT services sector (sector benchmark)

  • 65.5% of EU enterprises using paid cloud services used them for security software applications in 2025.[8]
  • 85.2% of EU enterprises using paid cloud services used them for email in 2025.[8]
  • 26.1% of EU enterprises using paid cloud services used computing platforms for application development, testing or deployment in 2025.[8]
  • 52.7% of EU enterprises with at least 10 employees used paid cloud-computing services in 2025.[8]
  • 71.5% of EU enterprises using paid cloud services used them for file storage in 2025.[8]
  • 71.7% of EU enterprises using paid cloud services used them for office software in 2025.[8]

Big Data in the software and IT services sector (sector benchmark)

  • Big-data analytics adoption averaged 14% among OECD enterprises with at least 10 employees, compared with 49% for cloud computing in the latest comparable data.[9]
  • 40% was the highest reported enterprise adoption rate for big-data analytics across OECD countries in the latest available data through 2023.[9]
  • 3% was the lowest reported enterprise adoption rate for big-data analytics across OECD countries in the latest available data through 2023.[9]
  • 14% of enterprises with at least 10 employees across the OECD used big-data analytics on average, based on 2022 data or the latest available year.[9]

IoT in the software and IT services sector (sector benchmark)

  • 27% of OECD enterprises used IoT technologies on average, compared with 49% using cloud computing in the latest comparable data.[9]
  • 6% was the lowest reported enterprise adoption rate for IoT technologies across OECD countries in the latest available data through 2023.[9]
  • 53% was the highest reported enterprise adoption rate for IoT technologies across OECD countries in the latest available data through 2023.[9]
  • 27% of enterprises with at least 10 employees across the OECD used Internet of Things technologies on average, based on 2023 or the latest available data.[9]

05 Statistics

Data & Analytics

Knowledge-base scale and data-quality controls are central. QIAGEN Digital Insights incorporated 5,000 new findings per day in 2024 and uses 40 integrated scientific and clinical databases.

Business intelligence in the bioinformatics industry

  • 40 integrated databases supported QIAGEN Digital Insights’ analysis and interpretation products in 2024, globally.[10]
  • 35,000 cited patents were included in QIAGEN Digital Insights’ bioinformatics knowledge base in 2024, supporting intelligence for research and clinical users.[10]
  • 5,000 new findings per day were incorporated into QIAGEN Digital Insights’ knowledge base in 2024, supporting genomic and biomedical intelligence.[10]
  • 90,000 users accessed QIAGEN Digital Insights’ disease insights daily in 2024, providing a company-reported usage KPI for bioinformatics intelligence products.[10]

Data analytics in the bioinformatics industry

  • Approximately 2.3 million genomic profiles had been analyzed through SOPHiA GENETICS’ platform by 2025, globally.[11]
  • Approximately 33,000 new genomic profiles were added monthly to SOPHiA GENETICS’ platform during 2025.[11]
  • More than 4 million patient tests had been analyzed in QIAGEN Digital Insights’ integrated clinical and scientific databases by 2024.[10]
  • 65,000 clinical reports were created monthly using QIAGEN Digital Insights analytics in 2024.[10]

Data Quality in the software and IT services sector (sector benchmark)

  • In 2025, 46% of organizations globally said they were fully confident in their data quality, across surveyed technology and business organizations.[12]
  • In 2025, 43% of organizations globally rated their data excellent for quality and completeness, across surveyed technology and business organizations.[12]
  • In 2025, 46% of organizations globally rated their data excellent for accuracy and integrity, across surveyed technology and business organizations.[12]
  • In 2025, 35% of organizations globally rated their data excellent for consistency and standardization, across surveyed technology and business organizations.[12]
  • In 2024, 95% of enterprise data leaders and practitioners reported a data-quality issue with a direct impact on business outcomes, across companies with at least $1 billion in revenue.[13]
  • In 2025, 34% of organizations globally rated their data excellent for relevance and suitability, across surveyed technology and business organizations.[12]

Data Governance in the software and IT services sector (sector benchmark)

  • In 2024, 35% of U.S. technology executives prioritized data governance among their data-management areas for the next 12 months.[1]
  • In 2024, 18.3% of organizations reported having a data-governance or catalog solution as part of their governance program, according to a global governance study.[14]
  • In 2024, 61% of supply-management organizations reported having a dedicated data-governance function, based on an Institute for Supply Management survey.[15]
  • In 2026, 76% of global data leaders said their company’s AI governance did not completely keep pace with employee use of AI technology.[14]
  • In 2024, 32% of global technology leaders prioritized data governance among their data-management areas for the next 12 months.[1]
  • In 2024, 81.7% of organizations reported having no data-governance or catalog solution as part of their governance program, according to a global governance study.[14]

KPIs in the bioinformatics industry

  • 90,000 daily users was QIAGEN Digital Insights’ reported usage KPI for disease-insight products in 2024.[10]
  • 65,000 monthly clinical reports was QIAGEN Digital Insights’ reported customer-output KPI in 2024.[10]
  • Approximately $100 million was QIAGEN Digital Insights’ reported sales KPI for 2023.[16]
  • Approximately 33,000 monthly new genomic profiles was SOPHiA GENETICS’ platform-growth KPI during 2025.[11]

06 Statistics

Strategy & Growth

Partnerships and acquisitions target faster compute, wider knowledge integration, and clinical use. QIAGEN and NVIDIA announced a 2026 collaboration combining Digital Insights knowledge with NVIDIA accelerated computing and BioNeMo.

Growth in the bioinformatics industry

  • Genomics Limited increased revenue 98% year over year to £11.1 million in 2024 from £5.6 million in 2023.[17]
  • QIAGEN Digital Insights represented approximately 5% of QIAGEN’s total sales in 2024.[18]
  • SOPHiA GENETICS increased total revenue 4.5% to $65.173 million in 2024 from $62.371 million in 2023.[19]

Differentiation in the bioinformatics industry

  • SOPHiA GENETICS generated $63.546 million from its SOPHiA DDM Platform in 2024, compared with $1.627 million from workflow equipment and services.[19]
  • QIAGEN’s QIAGEN Digital Insights business represented approximately 5% of total sales in 2024 and provided software for genomic-data analysis and interpretation.[18]

Mergers and acquisitions in the bioinformatics industry

  • Illumina completed its acquisition of Grail for approximately $7.1 billion in 2021 before announcing plans to divest the cancer-screening company in 2024.[20]
  • $42 billion of diagnostics mergers and acquisitions were recorded in 2025, with activity driven partly by AI clinical bioinformatics, spatial multi-omics and scalable molecular diagnostics.[21]

Strategic partnerships in the bioinformatics industry

  • Genomics Limited partnered with 11 major pharmaceutical and biotechnology organizations in 2024 while expanding long-term strategic relationships.[17]
  • SOPHiA GENETICS entered partnerships with MD Anderson Cancer Center, Complete Genomics, Element Biosciences, Myriad Genetics and A.D.A.M. in 2025.[11]
  • SOPHiA GENETICS had strategic relationships with AstraZeneca, Memorial Sloan Kettering Cancer Center, Microsoft and NVIDIA in 2025.[11]

07 Statistics

People & Workforce

Hiring constraints stay tight for genomics and data roles while remote and hybrid work remains common across software and IT.

Hiring in the bioinformatics industry

  • 124 new core-genomics customers were signed by SOPHiA GENETICS in 2025, reflecting commercial expansion in a bioinformatics-focused genomics software business.[11]
  • Up to 70% of genomics companies needing computer-science, data-science or machine-learning skills reported that recruiting candidates with those skills was difficult or very difficult in the United Kingdom.[22]

Remote Work in the software and IT services sector (sector benchmark)

  • 34.8% of global software and IT services respondents worked remotely in 2026, according to the Stack Overflow Developer Survey.[23]
  • 84% of technology-services employers agreed in 2025 that the ability to work remotely is important for employee retention.[24]
  • 6% of global respondents worked fully remotely in 2025, defined as spending less than one day per week in the office.[24]
  • 10% of technology-services respondents worked under fully flexible arrangements in 2025, allowing employees substantial control over remote work.[24]
  • 48% of U.S. software and IT professionals surveyed worked remotely in 2026, compared with 21% in France.[23]

Hybrid Work in the software and IT services sector (sector benchmark)

  • 56% of IT employees worked in hybrid arrangements in 2025, while 31% were fully remote and 13% attended the office daily.[25]
  • 55% of technology-services respondents worked in a hybrid arrangement in 2025, the highest share among industries measured by Cisco.[24]
  • 52% of U.S. employees with remote-capable jobs worked in hybrid arrangements in May 2026, according to Gallup.[26]
  • 47% of global respondents worked in hybrid arrangements in 2025, down from 63% in Cisco’s 2022 study.[24]
  • 61% of U.S. employees with remote-capable jobs preferred hybrid work in November 2025, compared with 33% preferring fully remote work.[26]

Employee Engagement in the software and IT services sector (sector benchmark)

  • 22.2% of global software and IT respondents were happy with their current professional role in 2026, while 32.6% were unhappy.[23]
  • 37% of exclusively remote U.S. employees were engaged in May 2026, compared with 34% of hybrid employees and 29% of on-site employees with remote-capable jobs.[26]
  • 74% of respondents approved of fully flexible hybrid policies in 2025, the highest positive sentiment among the policy types Cisco measured.[24]
  • 54% of exclusively remote U.S. employees were thriving in May 2026, compared with 52% of hybrid employees and 49% of on-site employees with remote-capable jobs.[26]
  • 92% of employees ranked collaboration and community as very important aspects of office culture in Cisco’s 2025 global study.[24]

DEI in the bioinformatics industry

  • 42.1% of Ginkgo Bioworks’ U.S. employees self-identified as an underrepresented gender and 14.1% as members of an underrepresented racial or ethnic group in science and engineering at December 31, 2023.[11]
  • 43% of employees were female and 29% were non-white or Caucasian at a biotechnology company as of February 12, 2024.[11]

Change Management in the software and IT services sector (sector benchmark)

  • 87% of SAP change-management respondents believed AI would influence change management during the five years following the 2025 survey.[27]
  • 44% of SAP change-management respondents identified requirements gathering as a challenge in 2025.[27]
  • 42% of SAP change-management respondents cited inability to scale change management to business needs as a challenge in 2025.[27]
  • 59% of SAP change-management respondents expected AI to automate manual processes in change management, according to the 2025 survey.[27]
  • 86% of SAP change managers said in 2025 that change management gives their business a competitive advantage.[27]

08 Statistics

Customer & Sales

Customer retention and usage scale show how platforms stick. SOPHiA GENETICS reported net dollar retention of 115% in 2025 with a churn rate of 0.1%.

Customer retention in the bioinformatics industry

  • 0.1% was SOPHiA GENETICS’ annualized customer churn rate in 2025.[28]
  • 96% was Schrödinger’s gross dollar retention rate for commercial customers in both 2025 and 2024.[11]
  • 115% was SOPHiA GENETICS’ net dollar retention rate in 2025, up from 104% in 2024.[11]

Customer acquisition in the bioinformatics industry

  • 528 core-genomics customers used SOPHiA GENETICS’ platform at December 31, 2025, compared with 472 at the end of 2024.[11]
  • 124 new core-genomics customers were signed by SOPHiA GENETICS in fiscal year 2025, compared with 92 in fiscal year 2024.[11]

09 Statistics

Marketing & Brand

Usage and citation signals concentrate around disease insights and genomic analytics platforms, including daily disease-insight access and large publication citation counts.

Marketing in the bioinformatics industry

  • 90,000 users gain disease insights daily from QIAGEN Digital Insights products worldwide in 2024.[18]
  • 65,000 reports are created monthly by clinical customers using QIAGEN Digital Insights worldwide in 2024.[18]
  • More than 1,051 healthcare institutions in 77 countries used SOPHiA GENETICS’ genomic analytics platform in 2026.[29]
  • More than 100,000 scientific publications cited QIAGEN Digital Insights products by 2024.[18]

Digital marketing in the bioinformatics industry

  • More than 600 leads were generated for BD Bio through a targeted 2024 webinar promotion strategy.[30]
  • 156 people attended the 2024 BioDiscovery webinar live after its digital promotion campaign.[31]
  • 31 audience questions were submitted during the 2024 BioDiscovery webinar promoted through digital channels.[31]
  • 651 registrants joined a 2024 BioDiscovery webinar promoted through email, newsletters, social media and the company website.[31]

Branding in the bioinformatics industry

  • More than 993 hospital, laboratory and biopharma customers used SOPHiA GENETICS’ platform worldwide at December 31, 2025.[11]
  • 2.6 million patients had been analyzed globally through SOPHiA GENETICS’ platform by 2026.[29]
  • 15 of the 20 largest global cancer centers were reported as users of SOPHiA GENETICS’ platform in 2026.[29]
  • SOPHiA GENETICS’ active customer base grew from 182 in 2016 to more than 993 in 2025.[11]

Social media in the bioinformatics industry

  • 371,838 LinkedIn followers were shown for QIAGEN in 2026.[32]
  • 139,914 LinkedIn followers were shown for SOPHiA GENETICS on a company post viewed in 2026.[32]
  • 143,991 LinkedIn followers were shown for SOPHiA GENETICS in November 2026.[33]

Influencer Marketing in the software and IT services sector (sector benchmark)

  • Across B2B companies, another 29% of marketing organizations planned to adopt influencer marketing within the next year in 2025, based on an Ipsos survey of 1,500 marketing leaders.[34]
  • Across technology companies, 64% of marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, according to Nielsen’s global marketing survey.[35]
  • Across B2B companies, 55% of marketing organizations were using influencers in 2025, based on an Ipsos survey of 1,500 marketing leaders.[34]
  • Across B2B companies, 43% of marketers reported outstanding results from their influencer programs in the 2025 B2B Influencer Marketing Report.[36]
  • Across B2B companies, 58% of marketing teams reported using an always-on influencer marketing approach in the 2025 B2B Influencer Marketing Report.[36]

10 Statistics

Operations & Execution

Turnaround time and throughput gains depend on workflow automation and tighter pipeline execution. Average turnaround fell from nine days to 48 hours after AdventHealth Orlando moved WGS in-house.

Process optimization in the bioinformatics industry

  • 86% fewer discrete processing steps were achieved after total laboratory automation at Geisinger’s core laboratory in Pennsylvania.[37]
  • WGS replaced at least 10 different validated laboratory processes in an England pathogen-genomics service.[38]
  • A streamlined FASTQ-to-report workflow reduced turnaround time by approximately 50% to 60% in Ontario genetic laboratories.[39]

Operational efficiency in the bioinformatics industry

  • SOPHiA GENETICS’ platform was adding approximately 33,000 new genomic profiles monthly at December 31, 2025.[11]
  • Average turnaround time fell from nine days to 48 hours after AdventHealth Orlando moved bacterial and mycobacterial WGS in-house.[40]
  • AdventHealth Orlando processed 78 bacterial and 705 mycobacterial isolates in-house during October 2023–September 2024.[40]
  • Bioinformatics platform profiles analyzed by SOPHiA GENETICS increased from approximately 80,000 in 2016 to 2.3 million in 2025.[11]

Quality management in the bioinformatics industry

  • 35,000 cited patents were included in the QIAGEN Digital Insights knowledge base in 2024.[18]
  • 5,000 new curated findings were added daily to QIAGEN Digital Insights in 2024.[18]
  • More than 4 million analyzed patient tests contributed data to the QIAGEN Digital Insights knowledge base in 2024.[18]
  • 40 integrated scientific and clinical databases formed the QIAGEN Digital Insights knowledge base in 2024.[18]

Outsourcing / Offshoring in the software and IT services sector (sector benchmark)

  • Across German digital-experience service providers, 7.6% of services for customer projects were delivered offshore in 2024.[41]
  • Across European organizations, 35% planned to increase their use of nearshore outsourcing in the 2024/2025 sourcing study.[42]
  • Across German digital-experience service providers, 13.2% of services for customer projects were delivered nearshore in 2024.[41]
  • Across EU enterprises sourcing business functions internationally during 2021–2023, 28.7% moved information and communication technology services abroad.[8]
  • Among German IT-service generalists, 19.5% of digital-experience services for customer projects were delivered nearshore in 2024.[41]

11 Statistics

Finance & Pricing

Pricing spans per-sample and per-hour rates, and cost reductions appear when throughput scales. A UC Davis core rate is $195 per sample for 2026 RNA-seq differential-expression analysis.

Pricing strategy in the bioinformatics industry

  • $195 per sample was the 2026 UC Davis Bioinformatics Core private-enterprise rate for RNA-seq differential-expression analysis.[43]
  • $600 per sample was the 2026 commercial rate at Nebraska’s Center for Biotechnology for single-cell or nuclei RNA-seq analysis.[44]
  • $232 per sample was the 2026 UC Davis Bioinformatics Core private-enterprise rate for human genome or exome SNP analysis.[43]
  • $246 per hour was the 2026 UC Davis Bioinformatics Core rate for private-enterprise custom bioinformatics analysis.[43]
  • $300 per sample was the 2026 commercial rate at Rutgers’ MaGIC core for single-cell RNA analysis.[45]

Cost reduction in the bioinformatics industry

  • $230,646 was saved by AdventHealth Orlando through in-house processing of bacterial and mycobacterial isolates during October 2023–September 2024.[40]
  • 17% was the reduction in staff costs reported after implementing WGS in an England pathogen-genomics service.[38]
  • 88% was the reduction in equipment maintenance and calibration cost per sample across the laboratories and platforms studied when throughput increased.[46]
  • 66% was the reduction in average cost per sample when a genomics laboratory increased annual throughput from 600 to 5,000 samples using Illumina MiSeq.[46]
  • 63.2% was the reduction in reagent and consumable cost per sample for an ONT MinION laboratory scaling from 600 to 5,000 samples annually.[46]

Profitability in the bioinformatics industry

  • 84% was QIAGEN’s gross margin in 2024, including its bioinformatics business within the company’s portfolio.[10]
  • $281.9 million was Tempus AI’s net loss in 2024 while it expanded genomics and data-analysis operations.[11]
  • 30% was Tempus AI’s year-over-year total revenue growth in 2024.[11]
  • $693.4 million was Tempus AI’s 2024 total revenue from genomics, data and services, including bioinformatics-enabled offerings.[11]

Financial planning in the bioinformatics industry

  • 24% was the increase in Tempus AI genomics revenue from 2023 to 2024.[11]
  • 43% was the increase in Tempus AI data-and-services revenue from 2023 to 2024.[11]
  • $1.7 billion was Illumina’s cash, cash equivalents, restricted cash and marketable securities at the end of 2024.[11]
  • $480.1 million was the 2024 free cash flow reported by Illumina in its annual report.[11]

12 Statistics

Product & Service

Platform activity is measured in curated outputs and ongoing profile ingestion. SOPHiA GENETICS added approximately 33,000 new genomic profiles monthly during 2025.

Product development in the bioinformatics industry

  • 5,000 new findings per day were added to QIAGEN Digital Insights’ curated bioinformatics knowledge base in 2024, globally.[10]
  • 6 market-leading products formed QIAGEN Digital Insights’ bioinformatics offering in more than 70 countries in 2024.[11]
  • Approximately $100 million was QIAGEN Digital Insights’ bioinformatics sales in 2023, before its planned investment expansion.[16]
  • 40 integrated scientific and clinical databases supported QIAGEN Digital Insights’ bioinformatics products in 2024, globally.[10]

Product lifecycle in the bioinformatics industry

  • 26 million curated findings made up QIAGEN Digital Insights’ proven knowledge base in 2024, globally.[10]
  • More than 100,000 scientific publications cited QIAGEN Digital Insights products in 2024, indicating sustained use across their product lifecycle.[10]
  • More than 4 million analyzed patient tests contributed data to QIAGEN Digital Insights’ clinical and scientific databases in 2024.[10]
  • 35,000 cited patents were represented in QIAGEN Digital Insights’ curated bioinformatics knowledge base in 2024.[10]

After-sales in the bioinformatics industry

  • 90,000 users gained disease insights daily through QIAGEN Digital Insights bioinformatics products in 2024, globally.[10]
  • More than 4 million patient tests had been analyzed by QIAGEN Digital Insights’ bioinformatics knowledge base by 2024, supporting customer interpretation services.[10]
  • 65,000 reports were created monthly by QIAGEN Digital Insights’ clinical customers in 2024, globally.[10]
  • Approximately 33,000 new genomic profiles were added monthly to SOPHiA GENETICS’ platform during 2025, reflecting ongoing customer-service activity.[11]

Value proposition in the bioinformatics industry

  • SOPHiA GENETICS’ platform had analyzed approximately 2.3 million genomic profiles by 2025, compared with about 80,000 profiles earlier in its operating history.[11]
  • More than 100,000 scientific publications cited QIAGEN Digital Insights products in 2024, indicating broad research utility.[10]
  • 65,000 clinical reports per month were generated with QIAGEN Digital Insights in 2024, supporting clinical interpretation workflows.[10]
  • More than 90,000 users accessed QIAGEN Digital Insights disease insights daily in 2024, demonstrating the platform’s scale for bioinformatics customers.[10]

13 Statistics

Sustainability & Ethics

Sustainability pressure ties to compute and data-center efficiency. One cited estimate says 73% lower carbon emissions when BOLT-LMM version 1 was upgraded to version 2.3.

Sustainability in the bioinformatics industry

  • Approximately 34% of bioinformatics carbon emissions could be reduced by switching from an average to a more efficient data centre, according to a 2022 study.[37]
  • 30% of EMBL’s electricity use came from data centres in 2025, equivalent to approximately 9 GWh annually.[47]
  • More than 20 metric tons of CO2e per year may be generated by the equipment of a typical 7-to-10-person life-sciences laboratory, according to the cited estimate used in bioinformatics sustainability research.[37]
  • Bioinformatics pipeline carbon footprints at EMBL ranged from grams to tonnes of CO2e per project in 2025.[47]

Ethics in the bioinformatics industry

  • 3.3 out of 4 was the mean concern score for collaborations with governments implicated in human-rights abuses among surveyed commercial genomics professionals in 2026.[48]
  • 92% of surveyed U.S.-based commercial genomics professionals were quite or extremely concerned about insufficient diversity in genomic datasets in 2026.[48]
  • 3.5 out of 4 was the mean concern score for lack of diversity in genomic datasets among surveyed commercial genomics professionals in 2026.[48]
  • 3.4 out of 4 was the mean concern score for uneven privacy regulation across jurisdictions among surveyed commercial genomics professionals in 2026.[48]

Carbon footprint in the bioinformatics industry

  • 73% lower carbon emissions were estimated when BOLT-LMM version 1 was upgraded to version 2.3 in a bioinformatics genome-wide association study.[37]
  • 11 to 15 kgCO2e was the estimated carbon footprint of selected human whole-genome assembly tasks in a 2022 bioinformatics study.[37]
  • Long-read assembly had a carbon footprint 3.2 times larger per million reads than short-read assembly in the measured bioinformatics tools.[37]
  • Approximately 34% of bioinformatics carbon emissions could be reduced by using a more efficient data centre instead of an average data centre, according to a 2022 study.[37]

15 Statistics

Globalization & Expansion

Scale depends on coverage across customers and field distribution. QIAGEN served more than 500,000 customers in more than 170 countries in 2024.

Globalization in the bioinformatics industry

  • QIAGEN served more than 500,000 customers in more than 170 countries in 2024 through a portfolio that included bioinformatics solutions.[18]
  • SOPHiA GENETICS generated $46.929 million of revenue from EMEA in 2024, compared with $11.300 million from North America, $4.054 million from APAC and $2.890 million from Latin America.[19]
  • SOPHiA GENETICS reported total revenue of $65.173 million in 2024, up from $62.371 million in 2023 and $47.560 million in 2022.[19]
  • SOPHiA GENETICS operated a direct sales team of more than 96 field representatives across 58 countries and used distributors in 46 countries at December 31, 2024.[54]

Supplier management in the bioinformatics industry

  • QIAGEN reported that its bioinformatics-enabled supply chain included raw materials, R&D services, finished goods, logistics and warehousing, IT services and licensing in 2024.[11]
  • QIAGEN manufactured products in the United States, Europe and China in 2024, with Chinese manufacturing serving the local market.[18]

Stakeholder management in the bioinformatics industry

  • QIAGEN served universities, research institutes, pharmaceutical and biotechnology companies, governments and law-enforcement agencies with bioinformatics and related services in 2024.[10]
  • More than 500,000 customers worldwide used QIAGEN products and services in 2024, including bioinformatics solutions.[18]

Distribution channels in the bioinformatics industry

  • QIAGEN used third-party distributors in certain markets alongside regional commercial teams covering the Americas, EMEA and Asia-Pacific/Japan in 2024.[18]
  • SOPHiA GENETICS supplemented its direct commercial team with distributors in 46 countries at December 31, 2024.[54]
  • QIAGEN operated a centralized distribution system with regional hubs responsible for local logistics functions in 2024.[18]

Key questions about the bioinformatics industry

How large is the global bioinformatics market in 2026?
The global bioinformatics market is estimated at $21.36 billion in 2026.
What technology shifts show up in 2026 activity?
AI is moving from pilots to workflows, and cloud bioinformatics becomes standard. In 2026, 87% of surveyed life-sciences companies had integrated AI agents into processes, products, or services.
Which companies lead the bioinformatics industry?
Roche stands out for clinical sequencing-analysis because it develops navify and sequencing-analysis solutions for clinical genomics, while Oxford Nanopore Technologies leads in nanopore sequencing and analysis since it develops nanopore sequencing technology and associated analysis workflows.
How is the market commonly segmented?
The market is commonly divided into knowledge-management tools, data-analysis platforms and services.
How much genomics work does pricing data point to for cloud secondary analysis?
Illumina states that secondary analysis of a 30–35x human whole genome typically costs $6–$10 per genome in the cloud.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Bioinformatics Industry Statistics. Gitnux. https://gitnux.org/bioinformatics-industry-statistics
MLA
Samuel Norberg. "Bioinformatics Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/bioinformatics-industry-statistics.
Chicago
Samuel Norberg. 2026. "Bioinformatics Industry Statistics." Gitnux. https://gitnux.org/bioinformatics-industry-statistics.

Sources & references

70 sources cited across this report

  1. kpmg.com
  2. infosys.com
  3. benchling.com
  4. pipebio.com
  5. techresearchinfo.com
  6. teksystems.com
  7. higherlogicdownload.s3.amazonaws.com
  8. ec.europa.eu
  9. oecd.org
  10. s28.q4cdn.com
  11. sec.gov
  12. riverbed.com
  13. anomalo.com
  14. informatica.com
  15. utah.ismworld.org
  16. corporate.qiagen.com
  17. s3.eu-west-2.amazonaws.com
  18. qiagen.com
  19. filecache.investorroom.com
  20. apnews.com
  21. deloitte.com
  22. bioindustry.org
  23. survey.stackoverflow.co
  24. newsroom.cisco.com
  25. computerworld.com
  26. gallup.com
  27. cio.com
  28. publicnow.com
  29. medschool.vanderbilt.edu
  30. viewonline.drugdiscoverynews.com
  31. getsmartacre.com
  32. linkedin.com
  33. ca.linkedin.com
  34. business.linkedin.com
  35. brand-news.it
  36. toprankmarketing.com
  37. academic.oup.com
  38. assets.publishing.service.gov.uk
  39. d3e30vlyff459p.cloudfront.net
  40. nanoporetech.com
  41. luenendonk.de
  42. whitelane.com
  43. bioinformatics.ucdavis.edu
  44. biotech.unl.edu
  45. bioinformagic.io
  46. frontiersin.org
  47. embl.org
  48. pmc.ncbi.nlm.nih.gov
  49. prnewswire.com
  50. gtia.org
  51. isc2.org
  52. cdn.sypher.eu
  53. pagerduty.com
  54. financialfilings.com
  55. thebusinessresearchcompany.com
  56. onetonline.org
  57. mordorintelligence.com
  58. grandviewresearch.com
  59. marketsandmarkets.com
  60. emea.illumina.com
  61. uclahealth.org
  62. fda.gov
  63. grants.nih.gov
  64. investor.illumina.com
  65. roche.com
  66. bgi.com
  67. agilent.com
  68. illumina.com
  69. nih.gov
  70. bls.gov